Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy

What Was Tested

Researchers studied Insulin Glargine and Insulin Lispro in this randomized controlled trial publication.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

Adults new to insulin therapy were enrolled in a multicenter, randomized, prospective, open-label, crossover study with 16 weeks on each treatment.

How the Study Was Run

The researchers set it up as a randomized, open-label, crossover and multicenter study.

Because people in this Insulin Glargine study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label Insulin Glargine study: the participants and staff both knew the treatment.

Each person switched between Insulin Glargine and the comparison at some point, usually with a gap in between.

Running at several centres spread the Insulin Glargine study over different clinics and patient groups.

Variables included glycosylated hemoglobin (HbA(1c)), hypoglycemia rate, fasting blood glucose (FBG), 2-hour postprandial blood glucose (ppBG), and rise in blood glucose after meals.

What Was Measured

The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 2, Fasting, Glycated Hemoglobin, Hypoglycemic Agents, Insulin and Insulin Glargine.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Insulin Glargine and Insulin Lispro.

Results are reported in around 10 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2004 (Clinical therapeutics), a journal based in United States.

More context: the Insulin Glargine compound page and the Insulin Lispro compound page.